drugset

drugset / Trial / NCT05579899

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

NCT05579899 ↗

Phase 2 Completed 119 enrolled Evommune, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis

Timeline

Start: 2022-09-27
Primary completion: 2023-07-27
Completion: 2023-07-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EVO101	Unknown	0.1 %	Topical

Indications